Monitor the October 14 reconvened meeting for vote results. If the proposal fails, management may face increased activist pressure; if it passes, it could facilitate future stockholder actions by written consent, potentially accelerating activist agendas.
Price Chart
Executive Summary
Tempest Therapeutics adjourned its reconvened special meeting on September 15, 2026, again due to insufficient votes to pass a proposal to eliminate supermajority voting requirements and permit stockholder action by written consent. The meeting will reconvene on October 14, 2026. The proposal requires 75% of outstanding votes, and management has engaged Sodali & Co. to solicit additional votes, indicating ongoing activist pressure from Versant Venture Capital and Matthew Angel.
Key Financial Metrics
Key Facts
- Special meeting reconvened on September 15, 2026, and adjourned again due to insufficient votes.
- Proposal requires affirmative vote of holders of at least 75% of outstanding shares.
- 10,760,144 shares (72.7% of 14,806,997 outstanding) were present, constituting a quorum.
- Meeting will reconvene on October 14, 2026 at 12:00 p.m. Eastern Time.
- Sodali & Co. engaged to assist with vote solicitation.
- Cross-filing context shows activist filings by Versant Venture Capital VI, L.P. (SC 13D/A on April 2, 2026) and Matthew Angel (SC 13D/A on March 25, 2026).
Financial Impact
No direct financial impact; outcome of vote could enable governance changes that may affect future capital allocation or activist influence.
Risk Factors
- Failure to pass the proposal may embolden activists to escalate their campaign.
- Continued adjournments signal management's difficulty in securing the 75% supermajority, potentially leading to a proxy fight or strategic alternatives.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-393155 |
| Document: 0001193125-26-393155-index-headers.html | 0001193125-26-393155 |
| Document: 0001193125-26-393155-index.html | 0001193125-26-393155 |
| Document: 0001193125-26-393155.txt | 0001193125-26-393155 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | DEF 14A | $0.5102 | awaiting T+20 | awaiting T+20 | $0.5110 (−0.16%) |
Oct 20, 2026 7d ago | DEFA14A | $0.5282 | awaiting T+20 | awaiting T+20 | $0.5110 (−3.26%) |
Oct 20, 2026 7d ago | 8-K | $0.5282 | awaiting T+20 | awaiting T+20 | $0.5110 (−3.26%) |
Oct 19, 2026 8d ago | 8-K | $0.5762 | awaiting T+20 | awaiting T+20 | $0.5110 (−11.32%) |
Oct 2, 2026 26d ago | EFFECT | $0.8112 | awaiting T+20 | awaiting T+20 | $0.5110 (+37.01%) |
Sep 25, 2026 4w ago | S-3 | $0.8316 $0.5102 | ▲ +38.65% | ▲ +38.62% | $0.5110 (+38.55%) |
Sep 17, 2026 5w ago | 8-K | $0.9680 $0.6240 | ▼ −35.54% | ▼ −35.74% | $0.5110 (−47.21%) |
Sep 16, 2026 5w ago | DEFA14A | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5110 (−42.91%) |
Sep 16, 2026 5w ago | 8-K | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5110 (−42.91%) |
Sep 11, 2026 6w ago | Press Release | $0.8117 $0.7601 | ▲ +6.36% | ▲ +8.23% | $0.5110 (+37.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers